Log in to save to my catalogue

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8422679

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a study involving patients with non–small-cell lung cancer with a
MET
exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was associated with a partial response in approximately half the patients. The main adverse event was peripheral edema.

Alternative Titles

Full title

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8422679

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8422679

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2004407

How to access this item